THE WOODLANDS, Texas, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today reported additional topline results for study ZA-302, the second pivotal efficacy study for Androxal®. The results of both pivotal studies, ZA-301 and ZA-302, have met the SPA co-primary endpoints as defined by the FDA.
Help employers find you! Check out all the jobs and post your resume.
